*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**Fusen Pharmaceutical Company Limited**
**福森藥業有限公司**
*(Incorporated in the Cayman Islands with limited liability)*
**(Stock Code: 1652)**

# VOLUNTARY ANNOUNCEMENT "COMPOUND POTASSIUM HYDROGEN PHOSPHATE INJECTION" APPROVED FOR MARKETING

The board of directors (the "**Board**") of Fusen Pharmaceutical Company Limited (the "**Company**", together with its subsidiaries, the "**Group**") is pleased to announce that "Compound Potassium Hydrogen Phosphate Injection" (trademark: Shanweixi 膳維喜) developed by Jiaheng (Zhuhai Hengqin) Pharmaceutical Technology Company Limited* (嘉亨(珠海橫琴)醫藥科技有限公司), a wholly-owned subsidiary of the Group, has obtained the approval for marketing from the National Medical Products Administration of the PRC as a phosphate supplement.

"Compound Potassium Hydrogen Phosphate Injection" is primarily used as a parenteral nutrition supplement and to treat hypophosphatemia in adult and pediatric patients when oral or enteral supplements are not feasible, insufficient, or contraindicated. As a new-generation phosphorus-potassium compound formula, it scientifically calibrates between monopotassium and dipotassium phosphate in order to rapidly treat phosphorus deficiency. The simultaneous potassium supplement helps stabilize membrane potential, thereby preventing the risk of rhabdomyolysis and arrhythmia induced by hypophosphatemia. According to China Medical and Pharmaceutical Economic Information Network, the domestic sales of Compound Potassium Hydrogen Phosphate Injection in the PRC were RMB343 million and RMB413 million in 2023 and 2024, respectively.

"Compound Potassium Hydrogen Phosphate Injection" is a Class B drug under the National Healthcare Security Administration* (國家醫療保障局). It has the characteristics of high safety, rapid onset, dual supplementation of phosphate and potassium, and multi-guideline consensus. The prescription of "Compound Potassium Hydrogen Phosphate Injection" developed by the Company is the same as the original reference preparations, while the quality of the products is strictly controlled to ensure that its quality is better than or consistent with the original preparation products, so as to ensure medical safety of patients. "Compound Potassium Hydrogen Phosphate Injection" provides a very favourable risk-

benefit ratio in the treatment of hypophosphatemia and phosphate supplements requiring parenteral nutrition, and in the improvement of laboratory findings and clinical symptoms in adult and pediatric patients.

''Compound Potassium Hydrogen Phosphate Injection'' is another important product of the Group, which further enriches the Group's product pipeline in the therapeutic area of nutritional supplements. The launch of this product provides more therapeutic options for adult and pediatric patients with hypophosphatemia and phosphate supplements requiring parenteral nutrition.

By order of the Board
**Fusen Pharmaceutical Company Limited**
**Mr. Cao Zhiming**
*Chairman and Executive Director*

Hong Kong, 29 December 2025

*As at the date of this announcement, the Board of the Company comprises Mr. Cao Zhiming (Chairman), Mr. Hou Taisheng, Mr. Chi Yongsheng and Ms. Meng Qingfen as executive Directors and Mr. Lee Kwok Tung Louis, Dr. To Kit Wa and Mr. Yu Ho Ming as independent non-executive Directors.*